Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease (Dapa-CKD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03036150
Recruitment Status : Completed
First Posted : January 30, 2017
Last Update Posted : August 20, 2020
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 12, 2020
Actual Study Completion Date : June 12, 2020
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):